Abstract: OBJECTIVE To analyze the epidemiological characteristics, drug resistance and risk factors of Burkholderia cepacia complex (BCC) infections in a hospital from 2013 to 2025, and to provide evidence-based support for the precise prevention and control of BCC infections, rational clinical drug use and the development of infection management strategies within the hospital. METHODS We retrospectively collected the sociodemographic characteristics, clinical diagnosis and treatment data and drug sensitivity test results of patients with BCC positive detection at the First Medical Center of the Chinese People's Liberation Army General Hospital from 2013 to 2025. The epidemiological characteristics, infection risk factors and drug resistance of BCC were analyzed. RESULTS A total of 850 patients were detected with BCC from 2013 to 2025, of which 334 (39.29%) were hospital-associated BCC infection. The overall infection rate showed a downward trend from 2013 to 2025 (χ_trend²=12.663, P_trend<0.001). A total of 296 co-infected patients accounted for 317 cases of co-infection. The lung was the most common infection site (65.62%), and sputum was the predominant specimen type (64.04%). A total of 158 cases (49.84%) were associated with clinically common multidrug-resistant organisms (MDRO). A total of 38 patients accounted for 42 cases of BCC monoinfection, with urinary tract infections (UTI) (52.38%) and bloodstream infections (BSI) (45.24%) identified as the predominant infections. Inpatient departments, surgery, central venous catheterization and co-occurrence with MDRO were risk factors for hospital-associated infections caused by BCC (P<0.05). BCC had the highest resistance rate to ofloxacin (33.60%), followed by levofloxacin (28.34%). The resistance rates to tigecycline, cefoperazone/sulbactam, imipenem, gentamicin, amikacin and cefepime were each below 5%. CONCLUSION Special attention should be paid to high-risk populations and departments for infection, to continuous monitoring of the epidemiological characteristics of BCC, to rational selection of antimicrobial agents, and to improvement of clinical diagnosis and treatment levels.